RESTON, Va., Nov. 26, 2007 (PRIME NEWSWIRE) -- TenthGate International, Inc. (Pink Sheets:TGTI) (www.tenthgate.biz) today announced the engagement of Adjuvant, Inc. of Centerville, Virginia to provide management consulting services for the planning and execution of technology commercialization to include licensing, co-development, joint ventures or acquisition opportunities. The Firm will undertake a search and engagement program to identify, screen and engage prospective business partners. Specific area of initial focus will be in the area of MPF(tm) (Melanocyte Protective Factor) and sunscreen protection technologies.
"Adjuvant will provide commercial program leadership and undertake a partnership development program for the MPF portfolio," said Adjuvant CEO Jeff Conroy.
"We see this relationship as a value accelerator for TenthGate and our shareholders," said Tim Novak, CEO of TenthGate. "Our medical holding company business approach enhanced by Adjuvant's broad transaction experience and global insight will enable us to stream-line our technology identification, assessment and commercialization" said Novak.
About TenthGate:
TenthGate International, Inc. is a medical holding company which is focused on the acquisition and development of life changing, health related technologies. The range of acquired technologies will include biotech/life sciences, diagnostic and unique medical devices. TenthGate has acquired five intellectual properties to date, two of which have obtained FDA approval and currently sell commercially. It has identified several additional technologies for acquisition.
The TenthGate International, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3179
About Adjuvant:
Adjuvant, Inc. is a strategic transaction advisory firm focused on the life science market. Adjuvant provides commercial development and business development services in therapeutics, platform technologies and medical devices. The Adjuvant BIOdB (www.biodb.com) is our global database of licensing priorities of over 2,500 biotechnology and pharmaceutical companies.
Safe Harbor Disclaimer
Except for the historical information contained herein, the matters discussed in this press release may include forward-looking statements or information. All statements, other than statements of historical fact, including, without limitation, those with respect to the objectives, plans and strategies of TenthGate International, Inc., and its affiliates, set forth herein and those preceded by or that include the words "believes," "expects," "given," "targets," "intends," "anticipates," "plans," "projects", "forecasts" or similar expressions, are forward-looking statements. Although the Company's management believes that such forward-looking statements are reasonable, it cannot guarantee that such expectations are, or will be, correct. These forward-looking statements involve a number of risks and uncertainties which could cause the Company's future results to differ materially from those anticipated. The Company assumes no obligation to update any of the information contained or referenced in this press release.